Approach to a 50-Year-Old Female with Heavy Uterine Bleeding

Step 1 - History (Detailed)

• Characterize the bleeding: onset, duration, frequency, amount (number of pads/tampons, clot passage), intermenstrual or postcoital nature
• Last menstrual period and menstrual pattern over recent months
• Associated symptoms: pelvic pain, dysmenorrhea, dyspareunia, pressure symptoms
• Systemic symptoms: easy bruising, nosebleeds, fatigue (suggesting coagulopathy or anemia)
• Medical history: obesity, PCOS, diabetes, thyroid disease, liver/renal disease
• Drug history: anticoagulants, hormones (exogenous estrogen, tamoxifen, HRT), IUCDs
• Family history: endometrial, colorectal (HNPCC/Lynch syndrome), or ovarian cancer
• Smear history and previous gynecological conditions

At age 50, approximately 50% of AUB is perimenopausal (incipient ovarian failure). However, the primary concern is excluding endometrial malignancy, which presents as postmenopausal or heavy perimenopausal bleeding in 90% of cases.

• Goldman-Cecil Medicine, International Edition

Step 2 - Physical Examination

• Vital signs and hemodynamic assessment (rule out acute hemorrhage)
• General: pallor (anemia), bruising (coagulopathy), signs of thyroid disease/Cushing's
• Abdominal exam: uterine or adnexal masses
• Speculum exam: vaginal/cervical source, polyps, ectropion, malignancy, trauma
• Bimanual exam: uterine size, tenderness, mobility, adnexal masses
• Pap smear if not up to date

Step 3 - Investigations

Immediate / Baseline Labs

The CBC, platelet count, coagulation studies (including screening for vWD), thyroid function tests, and fasting glucose are all part of the initial evaluation.

• Goldman-Cecil Medicine

Imaging

• Transvaginal ultrasound (TVUS): First-line imaging. Assesses endometrial thickness, uterine morphology, fibroids (especially submucosal), polyps, adenomyosis, ovarian pathology. 2D/3D USS or saline infusion sonogram (SIS/sonohysterogram) for better cavity evaluation.

Endometrial thickness >4 mm in postmenopausal women warrants biopsy; persistently thickened or abnormal endometrium in premenopausal women (>7 mm with PCOS) also warrants biopsy.

• Bailey & Love's Short Practice of Surgery, 28th Edition

Step 4 - Classify Using PALM-COEIN (FIGO 2011, ACOG Standard)

Structural causes (PALM) are diagnosed with imaging or histology; nonstructural causes (COEIN) are medical/functional diagnoses.

• Sabiston Textbook of Surgery

Step 5 - Endometrial Sampling (MANDATORY at This Age)

• Pipelle biopsy (outpatient, first-line) - office endometrial sampling
• Hysteroscopy + directed biopsy - best sensitivity/specificity for detecting endometrial pathology; recommended when Pipelle is inadequate or pathology is suspected on USS

• All women >45 with AUB (this patient meets criteria)
• Persistent intermenstrual bleeding
• Endometrial thickness >4 mm on USS in postmenopausal women
• Irregular/unscheduled bleeding on HRT after 3 months
• Younger women with risk factors: obesity, PCOS, tamoxifen, family history of Lynch syndrome

Hysteroscopy combined with endometrial biopsy improves sensitivity and specificity compared to either alone.

• Bailey & Love's

Step 6 - Management

Medical Management (First-line)

• NSAIDs (e.g., mefenamic acid) - reduce menstrual blood loss in ovulatory AUB
• Tranexamic acid - antifibrinolytic, effective for heavy menstrual bleeding
• Combined oral contraceptive pills - regulate cycles, reduce blood loss; also used for acute heavy bleeding (one OCP every 6 hours for 5-7 days; bleeding should stop within 24 hours)
• Progestogens (e.g., norethisterone, medroxyprogesterone) - for anovulatory bleeding; oppose estrogen
• Levonorgestrel IUD (Mirena) - highly effective for heavy menstrual bleeding, also provides endometrial protection
• GnRH agonists - for fibroids (used short-term pre-operatively)

Even profuse bleeding in hemodynamically stable anovulatory women can almost always be controlled by combined OCP every 6 hours for 5-7 days. Blood transfusion may be needed if anemia is severe.

• Goldman-Cecil Medicine

Surgical Management (if medical therapy fails or is contraindicated)

• Hysteroscopic polypectomy - for polyps
• Myomectomy / uterine artery embolization (UAE) - for symptomatic fibroids (UAE has ~31% eventual hysterectomy rate at follow-up)
• Endometrial ablation - for women who have completed childbearing; ~29% require hysterectomy by 5 years
• Hysterectomy - definitive treatment; reserved for those who fail/cannot tolerate medical therapy, or with malignancy/premalignancy

Hysterectomy should be reserved for patients who do not respond to or cannot tolerate medical therapy. Endometrial ablation and UAE are cost-effective alternatives with lower morbidity.

• Berek & Novak's Gynecology

Special Considerations at Age 50

• If postmenopausal (no period for 12 months): all bleeding is abnormal and requires immediate full workup for malignancy
• Tamoxifen users have 2-4x increased risk of endometrial cancer - investigate any AUB
• HRT users with unscheduled bleeding after 3 months require endometrial biopsy

Summary Algorithm

50F with heavy bleeding
        ↓
Rule out pregnancy (β-hCG)
        ↓
History + Physical Exam + Cervical smear
        ↓
Labs: CBC, coagulation, TFTs, glucose, prolactin
        ↓
Transvaginal Ultrasound
        ↓
Endometrial biopsy (age ≥45 - mandatory)
± Hysteroscopy if USS abnormal or Pipelle inadequate
        ↓
Classify cause (PALM-COEIN)
        ↓
Treat underlying cause:
  Medical → NSAIDs / Tranexamic acid / OCP / Progestin / LNG-IUD
  Surgical → Polypectomy / Myomectomy / UAE / Ablation / Hysterectomy

• Goldman-Cecil Medicine, International Edition, Block 38
• Sabiston Textbook of Surgery, 21st Ed., Block 29 (PALM-COEIN classification)
• Bailey & Love's Short Practice of Surgery, 28th Ed., Ch. 87
• Berek & Novak's Gynecology, Block 7
• Recent guidelines: SOGC Guideline No. 453 on Endometrial Ablation (2024) [PMID: 39168283]; SOGC Guideline No. 461 on Uterine Fibroids (2025) [PMID: 40562356]